Skip to main content
Erschienen in: Endocrine 2/2013

01.04.2013 | Original Article

Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development

verfasst von: Yan Li, Jie Hai, Lake Li, Xuehui Chen, Hua Peng, Meng Cao, Qinggui Zhang

Erschienen in: Endocrine | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

We aim to investigate the preventive and therapeutic effects of ghrelin on a rat NAFLD model and possible underlying mechanism. Sprague–Dawley rats were fed with high-fat diet for 8 weeks to induce NAFLD. A group of rats were also treated with ghrelin throughout the NAFLD induction. After 8 weeks, rats were sacrificed for liver injury measurements. Rats with NAFLD showed obvious histological changes including necrosis and inflammation foci, elevated serum enzyme (ALT and AST) levels, dysregulated hepatic lipid metabolism, increased formation of oxidative stress, and lipid peroxidation markers, up-regulated levels of pro-inflammatory cytokines and apoptotic cells in the liver. Treatment of ghrelin improved liver injury through counter-acting those events. The improvement of ghrelin was accompanied with a restoration of LKB1/AMPK and PI3 K/Akt pathways. Ghrelin treatment alone did not influence the healthy rat liver. In addition, “therapeutic” ghrelin administration (2 weeks) after the establishment of early NAFLD symptoms (4 weeks) in rats further proved the beneficial effects of ghrelin. In conclusion, administration of ghrelin could attenuate NAFLD-induced liver injury, oxidative stress, inflammation, and apoptosis partly through the action of LKB1/AMPK and PI3 K/Akt pathways.
Literatur
2.
Zurück zum Zitat J.K. Dowman, J.W. Tomlinson, P.N. Newsome, Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 33, 525–540 (2011)PubMedCrossRef J.K. Dowman, J.W. Tomlinson, P.N. Newsome, Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 33, 525–540 (2011)PubMedCrossRef
3.
Zurück zum Zitat E.E. Powell, W.G. Cooksley, R. Hanson, J. Searle, J.W. Halliday, L.W. Powell, The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11, 74–80 (1990)PubMedCrossRef E.E. Powell, W.G. Cooksley, R. Hanson, J. Searle, J.W. Halliday, L.W. Powell, The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11, 74–80 (1990)PubMedCrossRef
4.
Zurück zum Zitat M.R. Teli, O.F. James, A.D. Burt, M.K. Bennett, C.P. Day, The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22, 1714–1719 (1995)PubMedCrossRef M.R. Teli, O.F. James, A.D. Burt, M.K. Bennett, C.P. Day, The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22, 1714–1719 (1995)PubMedCrossRef
5.
Zurück zum Zitat R.C. Harmon, D.G. Tiniakos, C.K. Argo, Inflammation in nonalcoholic steatohepatitis. Expert. Rev. Gastroenterol. Hepatol. 5, 189–200 (2011)PubMedCrossRef R.C. Harmon, D.G. Tiniakos, C.K. Argo, Inflammation in nonalcoholic steatohepatitis. Expert. Rev. Gastroenterol. Hepatol. 5, 189–200 (2011)PubMedCrossRef
6.
Zurück zum Zitat N. Alkhouri, C. Carter-Kent, A.E. Feldstein, Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert. Rev. Gastroenterol. Hepatol. 5, 201–212 (2011)PubMedCrossRef N. Alkhouri, C. Carter-Kent, A.E. Feldstein, Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert. Rev. Gastroenterol. Hepatol. 5, 201–212 (2011)PubMedCrossRef
7.
Zurück zum Zitat G.H. Koek, P.R. Liedorp, A. Bast, The role of oxidative stress in non-alcoholic steatohepatitis. Clin. Chim. Acta 412, 1297–1305 (2011)PubMedCrossRef G.H. Koek, P.R. Liedorp, A. Bast, The role of oxidative stress in non-alcoholic steatohepatitis. Clin. Chim. Acta 412, 1297–1305 (2011)PubMedCrossRef
8.
Zurück zum Zitat M. Pan, Y.L. Song, J.M. Xu, H.Z. Gan, Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. J. Pineal Res. 41, 79–84 (2006)PubMedCrossRef M. Pan, Y.L. Song, J.M. Xu, H.Z. Gan, Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats. J. Pineal Res. 41, 79–84 (2006)PubMedCrossRef
9.
Zurück zum Zitat A. Inui, A. Asakawa, C.Y. Bowers, G. Mantovani, A. Laviano, M.M. Meguid, M. Fujimiya, Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 18, 439–456 (2004)PubMedCrossRef A. Inui, A. Asakawa, C.Y. Bowers, G. Mantovani, A. Laviano, M.M. Meguid, M. Fujimiya, Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 18, 439–456 (2004)PubMedCrossRef
10.
Zurück zum Zitat M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, K. Kangawa, Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656–660 (1999)PubMedCrossRef M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, K. Kangawa, Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656–660 (1999)PubMedCrossRef
11.
Zurück zum Zitat T.R. Castañeda, J. Tong, R. Datta, M. Culler, M.H. Tschöp, Ghrelin in the regulation of body weight and metabolism. Front. Neuroendocrinol. 31, 44–60 (2010)PubMedCrossRef T.R. Castañeda, J. Tong, R. Datta, M. Culler, M.H. Tschöp, Ghrelin in the regulation of body weight and metabolism. Front. Neuroendocrinol. 31, 44–60 (2010)PubMedCrossRef
12.
Zurück zum Zitat D.E. Cummings, D.S. Weigle, R.S. Frayo, P.A. Breen, M.K. Ma, E.P. Dellinger, J.Q. Purnell, Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346, 1623–1630 (2002)PubMedCrossRef D.E. Cummings, D.S. Weigle, R.S. Frayo, P.A. Breen, M.K. Ma, E.P. Dellinger, J.Q. Purnell, Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346, 1623–1630 (2002)PubMedCrossRef
13.
Zurück zum Zitat S.M. Pöykkö, E. Kellokoski, S. Hörkkö, H. Kauma, Y.A. Kesäniemi, O. Ukkola, Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546–2553 (2003)PubMedCrossRef S.M. Pöykkö, E. Kellokoski, S. Hörkkö, H. Kauma, Y.A. Kesäniemi, O. Ukkola, Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546–2553 (2003)PubMedCrossRef
14.
Zurück zum Zitat J. Tong, R.L. Prigeon, H.W. Davis, M. Bidlingmaier, S.E. Kahn, D.E. Cummings, M.H. Tschöp, D. D’Alessio, Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 59, 2145–2151 (2010)PubMedCrossRef J. Tong, R.L. Prigeon, H.W. Davis, M. Bidlingmaier, S.E. Kahn, D.E. Cummings, M.H. Tschöp, D. D’Alessio, Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 59, 2145–2151 (2010)PubMedCrossRef
15.
Zurück zum Zitat T. Waseem, M. Duxbury, H. Ito, Ghrelin ameliorates TNF-α induced antiproliferative and pro-apoptotic effects and promotes intestinal epithelial restitution. J. Am. Coll. Surg. 199, 16 (2004)CrossRef T. Waseem, M. Duxbury, H. Ito, Ghrelin ameliorates TNF-α induced antiproliferative and pro-apoptotic effects and promotes intestinal epithelial restitution. J. Am. Coll. Surg. 199, 16 (2004)CrossRef
16.
Zurück zum Zitat T. Waseem, M. Duxbury, H. Ito, S.W. Ashley, M.K. Robinson, Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery 143, 334–342 (2008)PubMedCrossRef T. Waseem, M. Duxbury, H. Ito, S.W. Ashley, M.K. Robinson, Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery 143, 334–342 (2008)PubMedCrossRef
17.
Zurück zum Zitat E. Gonzalez-Rey, A. Chorny, M. Delgado, Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130, 1707–1720 (2006)PubMedCrossRef E. Gonzalez-Rey, A. Chorny, M. Delgado, Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130, 1707–1720 (2006)PubMedCrossRef
18.
Zurück zum Zitat R. Wu, W. Dong, Y. Ji, M. Zhou, C.P. Marini, T.S. Ravikumar, P. Wang, Orexigenic hormone ghrelin attenuates local and remote organ injury after intestinal ischemia-reperfusion. PLoS ONE 3, e2026 (2008)PubMedCrossRef R. Wu, W. Dong, Y. Ji, M. Zhou, C.P. Marini, T.S. Ravikumar, P. Wang, Orexigenic hormone ghrelin attenuates local and remote organ injury after intestinal ischemia-reperfusion. PLoS ONE 3, e2026 (2008)PubMedCrossRef
19.
Zurück zum Zitat S.O. Işeri, G. Sener, B. Saglam, F. Ercan, N. Gedik, B.C. Yeğen, Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats. Regul Pept 146, 73–79 (2008)PubMedCrossRef S.O. Işeri, G. Sener, B. Saglam, F. Ercan, N. Gedik, B.C. Yeğen, Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats. Regul Pept 146, 73–79 (2008)PubMedCrossRef
20.
Zurück zum Zitat D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, O.W. Cummings, L.D. Ferrell, Y.C. Liu, M.S. Torbenson, A. Unalp-Arida, M. Yeh, A.J. McCullough, A.J. Sanyal, Nonalcoholic Steatohepatitis Clinical Research Network, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005)PubMedCrossRef D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, O.W. Cummings, L.D. Ferrell, Y.C. Liu, M.S. Torbenson, A. Unalp-Arida, M. Yeh, A.J. McCullough, A.J. Sanyal, Nonalcoholic Steatohepatitis Clinical Research Network, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005)PubMedCrossRef
21.
Zurück zum Zitat J. Aubert, K. Begriche, L. Knockaert, M.A. Robin, B. Fromenty, Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin. Res. Hepatol. Gastroenterol. 35, 630–637 (2011)PubMedCrossRef J. Aubert, K. Begriche, L. Knockaert, M.A. Robin, B. Fromenty, Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin. Res. Hepatol. Gastroenterol. 35, 630–637 (2011)PubMedCrossRef
22.
Zurück zum Zitat G.S. Salvesen, Caspases: opening the boxes and interpreting the arrows. Cell Death Differ. 9, 3–5 (2002)PubMedCrossRef G.S. Salvesen, Caspases: opening the boxes and interpreting the arrows. Cell Death Differ. 9, 3–5 (2002)PubMedCrossRef
23.
Zurück zum Zitat S. Ghavami, M. Hashemi, S.R. Ande, B. Yeganeh, W. Xiao, M. Eshraghi, C.J. Bus, K. Kadkhoda, E. Wiechec, A.J. Halayko, M. Los, Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 46, 497–510 (2009)PubMedCrossRef S. Ghavami, M. Hashemi, S.R. Ande, B. Yeganeh, W. Xiao, M. Eshraghi, C.J. Bus, K. Kadkhoda, E. Wiechec, A.J. Halayko, M. Los, Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 46, 497–510 (2009)PubMedCrossRef
24.
Zurück zum Zitat W.W. Winder, D.G. Hardie, AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 277, E1–E10 (1999)PubMed W.W. Winder, D.G. Hardie, AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 277, E1–E10 (1999)PubMed
25.
Zurück zum Zitat J.W. Han, X.R. Zhan, X.Y. Li, B. Xia, Y.Y. Wang, J. Zhang, B.X. Li, Impaired PI3 K/Akt signal pathway and hepatocellular injury in high-fat fed rats. World J. Gastroenterol. 28, 6111–6118 (2010)CrossRef J.W. Han, X.R. Zhan, X.Y. Li, B. Xia, Y.Y. Wang, J. Zhang, B.X. Li, Impaired PI3 K/Akt signal pathway and hepatocellular injury in high-fat fed rats. World J. Gastroenterol. 28, 6111–6118 (2010)CrossRef
26.
Zurück zum Zitat S.K. Panchal, H. Poudyal, T.V. Arumugam, L. Brown, Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J. Nutr. 141, 1062–1069 (2011)PubMedCrossRef S.K. Panchal, H. Poudyal, T.V. Arumugam, L. Brown, Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J. Nutr. 141, 1062–1069 (2011)PubMedCrossRef
27.
Zurück zum Zitat Z. Song, I. Deaciuc, Z. Zhou, M. Song, T. Chen, D. Hill, C.J. McClain, Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G894–G902 (2007)PubMedCrossRef Z. Song, I. Deaciuc, Z. Zhou, M. Song, T. Chen, D. Hill, C.J. McClain, Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G894–G902 (2007)PubMedCrossRef
28.
Zurück zum Zitat H.J. Park, D.A. DiNatale, M.Y. Chung, Y.K. Park, J.Y. Lee, S.I. Koo, M. O’Connor, J.E. Manautou, R.S. Bruno, Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J. Nutr. Biochem. 22, 393–400 (2011)PubMedCrossRef H.J. Park, D.A. DiNatale, M.Y. Chung, Y.K. Park, J.Y. Lee, S.I. Koo, M. O’Connor, J.E. Manautou, R.S. Bruno, Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J. Nutr. Biochem. 22, 393–400 (2011)PubMedCrossRef
29.
Zurück zum Zitat J. Ozer, M. Ratner, M. Shaw, W. Bailey, S. Schomaker, The current state of serum biomarkers of hepatotoxicity. Toxicology 245, 194–205 (2008)PubMedCrossRef J. Ozer, M. Ratner, M. Shaw, W. Bailey, S. Schomaker, The current state of serum biomarkers of hepatotoxicity. Toxicology 245, 194–205 (2008)PubMedCrossRef
30.
Zurück zum Zitat S. Seki, T. Kitada, T. Yamada, H. Sakaguchi, K. Nakatani, K. Wakasa, In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37, 56–62 (2002)PubMedCrossRef S. Seki, T. Kitada, T. Yamada, H. Sakaguchi, K. Nakatani, K. Wakasa, In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37, 56–62 (2002)PubMedCrossRef
31.
Zurück zum Zitat N. Chalasani, M.A. Deeg, D.W. Crabb, Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1497–1502 (2004)PubMedCrossRef N. Chalasani, M.A. Deeg, D.W. Crabb, Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1497–1502 (2004)PubMedCrossRef
32.
Zurück zum Zitat M.D. Weltman, G.C. Farrell, C. Liddle, Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111, 1645–1653 (1996)PubMedCrossRef M.D. Weltman, G.C. Farrell, C. Liddle, Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111, 1645–1653 (1996)PubMedCrossRef
33.
Zurück zum Zitat C.P. Day, From fat to inflammation. Gastroenterology 2006(130), 207–210 (2006)CrossRef C.P. Day, From fat to inflammation. Gastroenterology 2006(130), 207–210 (2006)CrossRef
34.
Zurück zum Zitat A.E. Feldstein, A. Canbay, P. Angulo, M. Taniai, L.J. Burgart, K.D. Lindor, G.J. Gores, Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437–443 (2003)PubMedCrossRef A.E. Feldstein, A. Canbay, P. Angulo, M. Taniai, L.J. Burgart, K.D. Lindor, G.J. Gores, Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437–443 (2003)PubMedCrossRef
35.
Zurück zum Zitat M. Moreno, J.F. Chaves, P. Sancho-Bru, F. Ramalho, L.N. Ramalho, M.L. Mansego, C. Ivorra, M. Dominguez, L. Conde, C. Millán, M. Marí, J. Colmenero, J.J. Lozano, P. Jares, J. Vidal, X. Forns, V. Arroyo, J. Caballería, P. Ginès, R. Bataller, Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 51, 974–985 (2010)PubMedCrossRef M. Moreno, J.F. Chaves, P. Sancho-Bru, F. Ramalho, L.N. Ramalho, M.L. Mansego, C. Ivorra, M. Dominguez, L. Conde, C. Millán, M. Marí, J. Colmenero, J.J. Lozano, P. Jares, J. Vidal, X. Forns, V. Arroyo, J. Caballería, P. Ginès, R. Bataller, Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 51, 974–985 (2010)PubMedCrossRef
36.
Zurück zum Zitat M.J. Sanders, P.O. Grondin, B.D. Hegarty, M.A. Snowden, D. Carling, Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J. 403, 139–148 (2007)PubMedCrossRef M.J. Sanders, P.O. Grondin, B.D. Hegarty, M.A. Snowden, D. Carling, Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J. 403, 139–148 (2007)PubMedCrossRef
37.
Zurück zum Zitat M.S. Lee, D. Kim, K. Jo, J.K. Hwang, Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem. Biophys. Res. Commun. 401, 92–97 (2010)PubMedCrossRef M.S. Lee, D. Kim, K. Jo, J.K. Hwang, Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem. Biophys. Res. Commun. 401, 92–97 (2010)PubMedCrossRef
38.
Zurück zum Zitat J. Dufour, P. Clavien, Signaling pathways in liver diseases, 2nd edn. (Springer, Heidelberg, 2010)CrossRef J. Dufour, P. Clavien, Signaling pathways in liver diseases, 2nd edn. (Springer, Heidelberg, 2010)CrossRef
39.
Zurück zum Zitat A. Chorny, P. Anderson, E. Gonzalez-Rey, M. Delgado, Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J. Immunol. 2008(180), 8369–8377 (2008) A. Chorny, P. Anderson, E. Gonzalez-Rey, M. Delgado, Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J. Immunol. 2008(180), 8369–8377 (2008)
40.
Zurück zum Zitat O. Kasımay, S.O. Işeri, A. Barlas, D. Bangir, C. Yeğen, S. Arbak, B.C. Yeğen, Ghrelin ameliorates pancreaticobiliary inflammation and associated remote organ injury in rats. Hepatol. Res. 36, 11–19 (2006)PubMedCrossRef O. Kasımay, S.O. Işeri, A. Barlas, D. Bangir, C. Yeğen, S. Arbak, B.C. Yeğen, Ghrelin ameliorates pancreaticobiliary inflammation and associated remote organ injury in rats. Hepatol. Res. 36, 11–19 (2006)PubMedCrossRef
41.
Zurück zum Zitat C.X. Huang, M.J. Yuan, H. Huang, G. Wu, Y. Liu, S.B. Yu, H.T. Li, T. Wang, Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides 30, 2286–2291 (2009)PubMedCrossRef C.X. Huang, M.J. Yuan, H. Huang, G. Wu, Y. Liu, S.B. Yu, H.T. Li, T. Wang, Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides 30, 2286–2291 (2009)PubMedCrossRef
42.
Zurück zum Zitat E. Cetin, M. Kanbur, N. Cetin, G. Eraslan, A. Atasever, Hepatoprotective effect of ghrelin on carbon tetrachloride-induced acute liver injury in rats. Regul Pept 171, 1–5 (2011)PubMedCrossRef E. Cetin, M. Kanbur, N. Cetin, G. Eraslan, A. Atasever, Hepatoprotective effect of ghrelin on carbon tetrachloride-induced acute liver injury in rats. Regul Pept 171, 1–5 (2011)PubMedCrossRef
Metadaten
Titel
Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development
verfasst von
Yan Li
Jie Hai
Lake Li
Xuehui Chen
Hua Peng
Meng Cao
Qinggui Zhang
Publikationsdatum
01.04.2013
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9761-5

Weitere Artikel der Ausgabe 2/2013

Endocrine 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.